Carcinoid Tumors
January 2019 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.
Authors:Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D
Institution:Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Medicine, Chicago, IL. Medicine, Chicago, IL.
Journal:Medicine (Baltimore). 2018 Nov;97(47):e13390. doi: 10.1097/MD.0000000000013390.

2:Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report.
Authors:Mei Z, Wang H, Ren S, Wei J, Gu Y
Institution:Department of Oncology, Sir Run Run Hospital, Nanjing Medical University. University. University, Nanjing, China.
Journal:Medicine (Baltimore). 2018 Nov;97(47):e13286. doi: 10.1097/MD.0000000000013286.

3:Long-term outcomes in pediatric appendiceal carcinoids: Turkey experience.
Authors:Akova F, Aydin E, Nur Eray Y, Toksoy N, Yalcin S, Altinay S, Tetikkurt US
Institution:Pediatric Surgery Department, Biruni University, Istanbul, Turkey.
Journal:Eur J Pediatr. 2018 Dec;177(12):1845-1850. doi: 10.1007/s00431-018-3258-z. Epub 2018 Sep 25.

4:An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Authors:Guadalupe E, Deshpande HA, Stein SM
Institution:Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut, USA.
Journal:Drugs Today (Barc). 2018 Aug;54(8):457-465. doi: 10.1358/dot.2018.54.8.2834461.

5:Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Authors:Kasi PM
Institution:College of Medicine and Oncology, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Journal:Drugs Today (Barc). 2018 Jul;54(7):423-432. doi: 10.1358/dot.2018.54.7.2834460.

6:Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?
Authors:Ramesh S, Kudachi S, Basu S
Institution:Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Parel, India; and Homi Bhabha National Institute, Mumbai, India. and Homi Bhabha National Institute, Mumbai, India. and Homi Bhabha National Institute, Mumbai, India
Journal:J Nucl Med Technol. 2018 Sep;46(3):292-294. doi: 10.2967/jnmt.118.210179. Epub 2018 Jun 8.

7:Nationwide overview of survival and management of appendiceal tumors in children.
Authors:Parikh PP, Perez EA, Neville HL, Hogan AR, Sola JE
Institution:DeWitt-Daughtry Family Department of Surgery, Division of Pediatric Surgery, University of Miami Miller School of Medicine, Miami, FL. Electronic address:
Journal:J Pediatr Surg. 2018 Jun;53(6):1175-1180. doi: 10.1016/j.jpedsurg.2018.02.080. Epub 2018 Mar 6.

8:Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
Authors:Tapia Rico G, Li M, Pavlakis N, Cehic G, Price TJ
Institution:Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia. South Wales, Australia. South Wales, Australia. Australia, Australia. Australia, Australia; University of Adelaide, Adelaide, South Australia, Australia. Electronic address:
Journal:Cancer Treat Rev. 2018 May;66:1-6. doi: 10.1016/j.ctrv.2018.03.002. Epub 2018 Mar 16.

9:Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
Authors:Brizzi MP, La Salvia A, Tampellini M, Sonetto C, Volante M, Scagliotti GV
Institution:Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy.; Department of Medical Oncology and Pathology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy.
Journal:BMC Cancer. 2018 Mar 20;18(1):311. doi: 10.1186/s12885-018-4205-0.

10:Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor.
Authors:Vesterinen T, Mononen S, Salmenkivi K, Mustonen H, Ilonen I, Knuuttila A, Haglund C, Arola J
Institution:a HUSLAB, Helsinki Biobank, Department of Pathology , University of Helsinki and Helsinki University Hospital , Helsinki , Finland. Helsinki , Helsinki , Finland. Hospital , Helsinki , Finland. University Hospital , Helsinki , Finland. , Helsinki , Finland. Hospital , Helsinki , Finland. University of Helsinki and Helsinki University Hospital , Helsinki , Finland. , Helsinki , Finland. Helsinki , Finland. Helsinki University Hospital , Helsinki , Finland.
Journal:Acta Oncol. 2018 Aug;57(8):1109-1116. doi: 10.1080/0284186X.2018.1441543. Epub 2018 Feb 20.

11:Endobronchial Treatment for Bronchial Carcinoid: Patient Selection and Predictors of Outcome.
Authors:Reuling EMBP, Dickhoff C, Plaisier PW, Coupe VMH, Mazairac AHA, Lely RJ, Bonjer HJ, Daniels JMA
Institution:Department of Surgery, VU University Medical Center, Amsterdam, the Netherlands. the Netherlands. Amsterdam, the Netherlands. Amsterdam, the Netherlands. Amsterdam, the Netherlands. Netherlands.
Journal:Respiration. 2018;95(4):220-227. doi: 10.1159/000484984. Epub 2018 Feb 12.

12:Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Authors:Dillon JS, Chandrasekharan C
Institution:Division of Endocrinology, University of Iowa Hospital & VA Medical Center, Iowa City, IA 52242, USA. Iowa City, IA 52242, USA.
Journal:Future Oncol. 2018 May;14(12):1155-1164. doi: 10.2217/fon-2017-0340. Epub 2018 Jan 19.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount

Medifocus Guidebook on Carcinoid Tumors

Updated: January 2, 2019
166 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: March 21, 2019

What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
Newcastle, England

"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
Nanaimo, British Columbia

"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
Agoura Hills, California

Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.